Heart failure & cardiomyopathies
Left Ventricular Assist Device Therapy in Cold and Dry Patients
Authors' conclusion
In cold and dry patients with end-stage heart failure, LVADs are associated with milder but significant improvements in functional capacity and quality of life with a similar incidence of adverse events and survival at 1 year.
Study context
- Population
- Adults with end-stage heart failure receiving left ventricular assist device (LVADs) between 2006 and 2017 in the Interagency Registry for Mechanically Assisted Circulatory Support databasepatients with complete clinical, echocardiographic, and functional capacity profiles
- Participants
- 10,310 adults
- Exposure
- Cold and dry vs cold and wet patients receiving LVADs
- Outcome
- Survival (mortality)
- Follow-up
- 1 year
Main finding
As reported in the abstract
- Cold and dry vs cold and wet: log-rank P =0.81
Observational data: associations, not effects.
Secondary outcomes
| Outcome | Cold and dry | Cold and wet | P value |
|---|---|---|---|
| Change in EuroQol · 1 year after LVADMilder improvement in cold and dry | +0.11 | +0.17 | P = 0.001 |
| Change in Kansas City Cardiomyopathy Questionnaire · 1 year after LVADMilder improvement in cold and dry | +26 | +31 | P = 0.031 |
| Change in 6-minute walk test distance · 1 year after LVADMilder improvement in cold and dry | change +194 feet | change +340 feet | P = 0.026 |
- Rate of hospitalizations · 1 year · no statistically significant difference
- P = 0.76
Follow-up
- Median follow-up
- 364 days (interquartile range, 326-381 days)
Pre-LVAD pulmonary capillary wedge pressure · before LVAD implantation
- Overall mean
- 25±9 mm Hg
Proportion cold and dry
- Cold and dry patients comprised
- 15%
Original publication
Left Ventricular Assist Device Therapy in Cold and Dry Patients. Circ Heart Fail. Published 8 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →